BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Erenumab (Aimovig) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Erenumab (Aimovig)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05684692-10362@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Erenumab (Aimovig): Phase 2 readout est. (NCT05684692)
DESCRIPTION:Erenumab (Aimovig)\, phase 2.\nStudy: Screening Trial for Pain 
 Relief in Schwannomatosis (STARFISH)\nEstimated primary completion: 30 Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/erenumab-
 aimovig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05684692
URL:https://assetmemo.bio/drug/erenumab-aimovig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655440-10362@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Erenumab (Aimovig): Phase 4 readout est. (NCT07655440)
DESCRIPTION:Erenumab (Aimovig)\, phase 4\, Migraine.\nStudy: Comparing Migr
 aine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients
  With Migraine (COMPACT-PM)\nEstimated primary completion: July 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/erenumab-aimovig#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07655440
URL:https://assetmemo.bio/drug/erenumab-aimovig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
